EchoGo Amyloidosis vs Zio XT ECG Monitoring System
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo Amyloidosis, is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing existing echocardiogram video clips. Tool B, Zio XT ECG Monitoring System, offers continuous wearable ECG monitoring for up to 14 days, utilizing AI for the detection and diagnosis of various cardiac arrhythmias. While both are FDA-cleared AI tools in cardiology, they address different clinical needs: one focuses on a specific structural heart condition through imaging analysis, and the other on electrical rhythm disorders via extended monitoring.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is designed as an AI-powered screening tool to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. The Zio XT ECG Monitoring System, conversely, is a wearable biosensor for continuous cardiac monitoring, primarily focused on accurate arrhythmia detection and diagnosis over a period of up to 14 days.
EchoGo Amyloidosis analyzes existing echocardiogram video clips using AI to identify suspected cardiac amyloidosis based on echocardiographic markers. In contrast, the Zio XT system uses a wearable, single-lead ECG biosensor to continuously collect cardiac data for up to 14 days, which is then analyzed by an FDA-cleared deep-learned AI algorithm and expert review.
EchoGo Amyloidosis processes data from standard echocardiograms, requiring no additional patient interaction beyond the imaging procedure itself. The Zio XT system involves a water-resistant, wearable biosensor that patients wear for up to 14 days, designed for comfort without external leads and includes a patient-activated button for symptomatic event logging.
For EchoGo Amyloidosis, inpatient analysis is covered by Medicare under NTAP Code ICD-10 XXE2X19 at $1,000 per analysis, while outpatient analysis uses HCPCS Code C9786 (Clinical APC Code 574) at $285 per analysis, covered by Medicare and select commercial insurers. For Zio XT, Medicare rates for its service under CPT codes 93247 (greater than 7 days up to 15 days) and 93243 (greater than 48 hours up to 7 days) were proposed at approximately $229-$260.35.
EchoGo Amyloidosis provides a diagnostic output indicating whether the echocardiogram is 'suggestive' or 'not suggestive' of cardiac amyloidosis, along with analysis of various echocardiographic markers. The Zio XT system delivers accurate arrhythmia detection and diagnosis based on continuous ambulatory cardiac monitoring data collected over the monitoring period.
More Comparisons
Backers
Who funded each tool's parent company.